The Failure in NGF Maturation and its Increased Degradation as the Probable Cause for the Vulnerability of Cholinergic Neurons in Alzheimer’s Disease

@article{Cuello2006TheFI,
  title={The Failure in NGF Maturation and its Increased Degradation as the Probable Cause for the Vulnerability of Cholinergic Neurons in Alzheimer’s Disease},
  author={A. Claudio Cuello and Martin A Bruno},
  journal={Neurochemical Research},
  year={2006},
  volume={32},
  pages={1041-1045}
}
This short review discusses the arguments to consider the dismetabolism of the pathway responsible for both the maturation and degradation of NGF as the culprit of vulnerability of the forebrain cholinergic system to the Alzheimer’s disease neuropathology. This summary includes information regarding a novel metabolic cascade converting Pro-NGF to mature NGF in the extracellular space and its ultimate degradation by a metalloprotease. It also describes how this pathway is altered in Alzheimer’s… 

The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease.

TLDR
The physiological role of NGF and its biological significance to cholinergic neurons of the CNS is discussed, the evidence for a dysregulation of the NGF metabolism in Alzheimer's disease and Down syndrome is presented, and the trophic factor hypothesis is revived.

Impact of the NGF Maturation and Degradation Pathway on the Cortical Cholinergic System Phenotype

TLDR
It is demonstrated that a pharmacologically induced chronic failure in extracellular NGF maturation leads to a reduction in mNGF levels, proNGF accumulation, cholinergic degeneration, and cognitive impairment in rats, and that inhibiting NGF degradation increases endogenous levels of the mature neurotrophin and increases the density of cortical cholinerential boutons.

Elevated Levels of miR-144-3p Induce Cholinergic Degeneration by Impairing the Maturation of NGF in Alzheimer’s Disease

TLDR
It is demonstrated that levels of miR-144-3p are increased in the hippocampi and the medial prefrontal cortex of an APP/PS1 mouse model of AD and identified a potential therapeutic target for AD.

Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF

TLDR
The intent of this review is describing available experimental and clinical data related to AD therapy, priming to gain additional facts associated with the importance of NGF for AD treatment, and encapsulated cell biodelivery (ECB) as an efficient tool for NGF delivery.

Nerve growth factor as a paradigm of neurotrophins related to Alzheimer's disease

TLDR
In this scenario, the so‐called trophic action exerted by NGF (and possibly also by other neurotrophins) in these targets neurons is actually the result of an anti‐amyloidogenic activity.

activators of the Trk receptors for neuroprotection.

TLDR
The evidence supporting the neurotrophin system's role in preventing neurodegeneration is discussed and some of the pharmacological strategies being pursued to develop effective therapeutics targeting neurotophin function are surveyed.

Transgenic Mice with Chronic NGF Deprivation and Alzheimer's Disease-Like Pathology Display Hippocampal Region-Specific Impairments in Short- and Long-Term Plasticities

TLDR
It is reported that AD11 mice display age-dependent short- and long-term DG plasticity deficits, while CA1 plasticity remains relatively spared, and that both structures exhibit enhanced glutamatergic transmission under lower, yet physiological, neurotransmitter release conditions.

Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease

TLDR
The results suggest that the neurotrophic effects of CBL might involve modulation of the pro‐NGF/NGF balance and a concomitant protection of cholinergic neurons.

Small molecule activators of the Trk receptors for neuroprotection

TLDR
The evidence supporting the neurotrophin system's role in preventing neurodegeneration is discussed and some of the pharmacological strategies being pursued to develop effective therapeutics targeting neurotophin function are surveyed.

References

SHOWING 1-10 OF 20 REFERENCES

Altered synaptic function in Alzheimer's disease.

NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients.

The Precursor Pro-Nerve Growth Factor Is the Predominant Form of Nerve Growth Factor in Brain and Is Increased in Alzheimer's Disease

TLDR
ProNGF is the predominant form of NGF in mouse, rat, and human brain tissue, whereas little or no mature NGF is detected, indicating that it is this precursor form, proNGF, that accumulates in AD.

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

TLDR
Demonstration of selective degeneration of neurons of the nucleus basalis of Meynert represents the first documentation of a loss of a transmitter-specific neuronal population in a major disorder of higher cortical function and points to a critical subcortical lesion in Alzheimer's patients.

Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade.

  • M. BrunoA. Cuello
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2006
In this report, we provide direct demonstration that the neurotrophin nerve growth factor (NGF) is released in the extracellular space in an activity-dependent manner in its precursor form (proNGF)

Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis

TLDR
The present findings indicate that AD is characterized by a widespread increase in cortical and subcortical NGF, and the AD-related decline in NGF found in nbM is consistent with the possibility of impaired retrograde transport of NGF to this region.

Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies.

TLDR
Brain specimens from middle-aged and elderly normal as well as demented subjects and patients with provisional clinical diagnosis of other neurological and psychiatric diseases were assessed histologically, finding that terminal 'cerebral hypoxia' is responsible for the depletion of these brain constituents.

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors.

TLDR
Stimulation of m1 and m3 receptor subtypes with carbachol increased the basal release of APP derivatives within minutes of treatment, indicating that preexisting APP is released in response to receptor activation and protein kinases mediate neurotransmitter receptor-controlled APP processing.

A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat.

TLDR
The notion that endogenously produced NGF acting through TrkA receptors is involved in the maintenance of the cholinergic phenotype in the normal, adult rat brain supports the idea that NGF normally plays a role in the continual remodeling of neural circuits during adulthood and contributes to therapeutic strategies for central nervous system degeneration and trauma.

Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas.

TLDR
Decreased levels of BDNF may constitute a lack of trophic support and, thus, may contribute to the degeneration of specific neuronal populations in the AD-affected brain, including the basal forebrain cholinergic system.